US Patent

US11771701 — Methotrexate formulation

Method of Use · Assigned to Therakind Ltd · Expires 2034-10-29 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a liquid pharmaceutical composition containing methotrexate free acid and a buffer, with a pH range of 6.5 to 8.2.

USPTO Abstract

A liquid pharmaceutical composition comprises methotrexate free acid and a buffer, wherein the pH of the composition is in the range of 6.5 to 8.2. Processes for preparation of the liquid pharmaceutical composition are also described. The liquid pharmaceutical composition is useful in therapy.

Drugs covered by this patent

chembl-chembl34259 (METHOTREXATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3700`	—	chembl-chembl34259

Patent Metadata

Patent number: US11771701
Jurisdiction: US
Classification: Method of Use
Expires: 2034-10-29
Drug substance claim: No
Drug product claim: Yes
Assignee: Therakind Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.